Upload
voliem
View
240
Download
0
Embed Size (px)
Citation preview
Transcriptional Regulation of Drug Metabolizing Enzymes
Anna Radominska-Pandya
Department of Biochemistry and Molecular Biology
University of Arkansas for Medical Sciences
Little Rock, Arkansas, US
October 2010; Gdansk University of Technology
Regulation of Drug Metabolizing Enzymes
• Transcriptional Regulation
– A transcription factor is a protein that binds to specific parts of DNA and is part of the system that controls the transcription of genetic information from DNA to RNA.
– Compounds can regulate these transcription factors by permitting (acting as an activator), or preventing (acting as a repressor) the presence of RNA polymerase, the enzyme which activates the transcription.
• Constitutive Regulation
– A constitutive gene or constitutive expression describes a gene that is transcribed continually and therefore, is present at a constant level in the cell.
Transcriptional Regulation
Phase I Enzymes
Regulation by Ligand Activated Transcriptions Factors: Phase-I Enzymes
Nrf2 AhR PPAR LXR FXR VDR PXR CAR GR
CYP1A1 + + Ind.
CYP1A2 + Ind.
CYP1B1 +
CYP2A6 + + Ind.
CYP2B1 +
CYP2B6 - + + + Ind.
CYP2C8 + +
CYP2C9 + + + +
CYP2C19 + + +
CYP3A4 - + + + + Ind.
CYP7A1 + - - -
ALDH1 + +
ALDH3 +
NQO1 + +
CYP3A Regulation
• Diverse drugs activate through heterodimer complex
• Protect against xenobiotics
• Cause drug-drug interactions
T.M. Wilson, S. A. Kliewer 2002:1, 259-266
CYP3A Inducers Activate PXR
rifampicin
PCN
dexamethasone
RU486
clotrimazole
Reporter activity (fold)
troglitazone
1 3 5 7 9 11 13 15 17 19
tamoxifen
Cell-basedreporter assay
S.A. Kliewer
Human
Rabbit
Rat
Regulation of Target Genes by PPAR:RXR Heterodimers
• Fatty acids serve as transcriptional inducers and substrates of enzymes involved in the lipid homeostasis.
steroids
metabolism & excretion
acetyl-CoA
metabolism & excretion
bile acids
PXR/CAR
SF-1 LXRFXR
PXR/CAR
FXRPXR/CAR
LXR
CYP3AsCYP2CsCYP2Bs
CYP11ACYP11BCYP21
CYP7A1
CYP3AsCYP2CsCYP2Bs
Cholesterol
SREBP
Transcriptional Regulation
UDP-GLucuronosyltransferases
Ritter JK, 1992
UGT1A Gene Cluster and Putative Protein Structure in Humans
Radominska-Pandya A, 1999
Regulation by Ligand Activated Transcriptions Factors: Phase-II Enzymes
Nrf2 AhR PPAR LXR FXR VDR PXR CAR GR
SULTs + +
SULT2A1 - + + + + +
UGT1A1 + + + +
UGT1A3 + +
UGT1A4 + +
UGT1A6 + + +
UGT1A9 + + +
UGT2B1 +
UGT2B4 + +
UGT2B7
GSTs + + + +
Major Receptors Involved in UGT Regulation
Receptor/
PartnerLigands and Inducers
Target
UGT GeneReference
hPXR/RXRPregnanolone, Corticosterone (CCS), Bile Acids
(BA), Rifampicin (Rif), Dexamethasone (Dex)
1A1
1A6
1A3
1A4
Xie/Radominska/Tukey (2001)
Xie/Radominska/Tukey (2003)
Li/Radominska (Unpublished)
Li/Radominska (Unpublished)
CAR/RXR Phenobarbital, Androstane Metabolites () 1A1
1A6
Sugatani (2001)
Xie/Radominska/Tukey (2003)
LXR/RXR Oxysterols, Bile Acids 1A3 Barbier (2006)
AhR/ARNTPolycylic Aromatic Hydrocarbons (PAHs),
Halogenated Aromatic Hydrocarbons (HAHs), β-Naphthoflavone (BNP)
1A1
1A6
1A3
1A4
Yueh (2003)
Sugatani (2004)
Li/Radominska (Unpublished)
Li/Radominska (Unpublished)
PPAR/RXR
(α and γ)Fatty Acids, Oxidized Fatty Acids, Hypolipidemic
Fibrates, Glitazones1A9 Barbier (2003)
FXR/RXRBile Acids, Chenodeoxycholic acid (CDCA),
Lithocholic Acid (LCA)
2B4
2B7
Barbier (2003)
Radominska (2005)
ER/ER Estradiol (E2)
1A3
1A10
2B17Radominska (2007)
Abbreviations: PXR (Pregnane X Receptor); RXR (Retinoid X Receptor); CAR (Constitutive Androstane Receptor); FXR (FarnesoidX Receptor); AhR (Arylhydrocarbon Receptor); ARNT (AhR Nuclear Translocator); LXR (Liver X Receptor); PPAR (PeroxisomeProliferator-Activated Receptor); ER (Estrogen Receptor)
Pregnane X Receptor (PXR) and Constitutive Androstane Receptor
(CAR)
Regulation of UGT1A1 and UGT1A6 Expression
Xie, et al. Nature 2000. 406, 435-439
Xie, et al. PNAS 2001. 98, 3375-3380
Creation of Transgenic Mice Expressing hPXRand Constitutively Activated hPXR (VP-hPXR)
Northern and Western Blot Analysis of UGT1A Expression
A. Activation of UGT1A6, UGT1As, and CYP3A11 mRNA in Alb-VP-hPXRtransgenic mice visualized by Northern Blot
B. Activation of UGT1A mRNA by Rif in Alb-hPXR transgenic mice visualized by Northern Blot
C. Liver microsomes were prepared from wild type and VP-hPXR mice and subjected to Western Blot analysis using anti-UGT1A and specific anti-UGT1A1 antibodies
Xie, et al. PNAS 2002.
C
A. Substrates for UGT1A Family
B. Substrates for UGT1A9
Increased UGT1A Expression: Increased Glucuronidation
• Glucuronidation activities were measured for:
– Xenobiotics:• pNP, PhIP
– Corticosteroids:• Corticosterone (CCS),
Cortisone, Cortisol
– Thyroid hormones:• 3,3’,5’-triiodothyronine (rT3),
thyroxine (T4)
Xie, et al. PNAS 2002.
Summary
• The mechanism of PXR/CAR mediated induction of UGT1A1 and 1A6 was delineated (Xie, et al. PNAS 2002.)
• VP-hPXR mice provide a “gain-of-function” in vivo model to help identify hPXR target genes
• UGT1A1 and 1A6 were identified as PXR/CAR target genes• Both phenobarbital and rifampicin induce UGT1A1 expression
via CAR and PXR– This explains the effectiveness of these drugs in treating Crigler-Nijjar
disease and Gilbert syndrome• Both diseases lead to hyperbilirubinemia (accumulation of bilirubin in serum)
• hPXR represents a key protective mechanism of UGT up-regulation to insure the elimination of:– Bilirubin– Thyroxine– Corticosteroids– Some carcinogens
• UGT1A3 and 1A4 may be gene targets for PXR
Suppression of UGT2B7 mRNA expression by FXR and Lithocholic
Acid (LCA)
LCA Suppresses the UGT2B7 Gene Expression in Caco-2 Cells as Demonstrated By Real Time RT-
PCR
Suppression of UGT2B7 mRNA by atRA and 9-cis RA and the Effect of the RAR Antagonist, TTNPB
atRA - all trans Retinoic Acid
TTNPB - (E)-4-[2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl-1-propenyl]benzoic acid
RAR - Retinoic Acid Receptor
Localization of the FXR Response Region in the Human 1.3 kb UGT2B7 Promoter by Progressive
Deletion Analysis
NFRE in the UGT2B7 Promoter is Required for Suppression by FXR
• ApoA1 (Apoprotein A1)– Negative FXR Response element (NFRE) – Novel Element: GATCCTTTGAACTCT
• UGT2B7– Putative Negative FXR response element (NFRE)– Consensus sequence: GATCCTTGAACTCT - 148 bp upstream of the
transcription start site
GATCCTTGATATTA
LuciferaseP-1328
NFREBARE
P-1315 NFREΔLuciferaseBARE
Mutation of the NFRE Relieves UGT2B7 Inhibition
EMSA Binding Analysis Confirms the Role of NFRE in UGT2B7 Gene Suppression
A. Labeled NFRE ProbeB. Labeled IR-1 Probe C. Labeled NFRE Probe NFRE with Mutant
IR-1 and CREB oligonucleotides used as non-specific competitors
• Competition experiments were performed by adding a 0, 50, and 100-fold molar excess of the indicated unlabeled probes.
• Sites were 32P-labeled and used as probes and incubated with 5 ug of Caco-2 nuclear extract in gel mobility shift assay.
• The specific FXR/RXR complex is indicated by an arrow.
Conclusions
• Human UGT2B7 is a target gene of LCA-activated FXR
– UGT2B7 transcription is suppressed by LCA
• LCA suppression occurs via FXR binding to a novel NFRE in the UGT2B7 promoter
• Suppression of UGT2B7 expression might occur under pathological conditions that are known to produce significant levels of LCA
– Ex) liver damage and/or cholestasis,
Practice Questions